Lantern Pharma Inc. Common Stock
Veridion Score
Composite trend over time
Why is LTRN moving today?
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for LTRN.
LTRN insider activity
Lantern Pharma Inc. Common Stock
2 insiders bought in the last 90 days
Net buying: $200K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | 2026-05-12 | Schalop Lee Troy | Insider | buy | $2.06 | 48,544 | 48,544 | $100K | SEC Form 4 |
| 2026-05-14 | 2026-05-12 | KEYSER D JEFFREY | Insider | buy | $2.06 | 48,544 | 94,303 | $100K | SEC Form 4 |
LTRN contract awards, year to date.
Public federal awards linked to this ticker.
LTRN lobbying filings, year to date.
Registered lobbying filings matched to Lantern Pharma Inc. Common Stock.